Aura Biosciences(AURA) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights Positive Phase 2 End of Study Data with Bel-sar in Early-Stage Choroidal Melanoma; Ongoing Phase 3 CoMpass Trial Recently Received Authorization to Start Enrolling Patients in Europe Multiple Clinical Complete Responses Observed with Single Low Dose of Bel-sar in Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC); Phase 1 Expansion Preparation in Progress Strong Cash Position Expected to Suppo ...